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Abstract
Introduction: Providing private antiretroviral therapy (ART) care for public sector patients could increase access to ART in
low- and middle-income countries. We compared the costs and outcomes of a private-care and a public-care ART program
in South Africa.
Methods: A novel Markov model was developed from the public-care program. Patients were first tunneled for 6 months in
their baseline CD4 category before being distributed into a dynamic CD4 and viral load model. Patients were allowed to
return to ART care from loss to follow up (LTFU). We then populated this modeling framework with estimates derived from
the private-care program to externally validate the model.
Results: Baseline characteristics were similar in the two programs. Clinic visit utilization was higher and death rates were
lower in the first few years on ART in the public-care program. After 10 years on ART we estimated the following outcomes
in the public-care and private-care programs respectively: viral load ,1000 copies/ml 89% and 84%, CD4 .500 cells/ml 33%
and 37%, LTFU 14% and 14%, and death 27% and 32%. Lifetime undiscounted survival estimates were 14.1 (95%CI 13.2–
14.9) and (95%CI 12.7–14.5) years with costs of 18,734 (95%CI 12,588–14,022) and 13,062 (95%CI 12,077–14,047) USD in the
private-care and public-care programs respectively. When clinic visit utilization in the public-care program was reduced by
two thirds after the initial 6 months on ART, which is similar to their current practice, the costs were comparable between
the programs.
Conclusions: Using a novel Markov model, we determined that the private-care program had similar outcomes but lower
costs than the public-care program, largely due to lower visit frequencies. These findings have important implications for
increasing and sustaining coverage of patients in need of ART care in resource-limited settings.
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Introduction
Expanding capacity to deal with the HIV epidemic is a
formidable task in low- and middle-income countries given the
scale of the epidemic and the limited public health infrastructure.
While much has been achieved to make antiretroviral therapy
(ART) affordable, access to care is still inadequate. According to
the latest UNAIDS report, only 46% of those who were in need
had started ART by the end of 2010 in low- to middle-income
countries [1].
One way to expand access to ART and improve retention
within ART care for public sector patients is to utilize the private
sector. In many low- and middle-income countries a high
proportion of doctors work in the private sector [2]. Contracting
private doctors to initiate ART and follow up public sector
patients in their private rooms according to the public sector
guidelines has been successfully implemented in Botswana [2] and
other developing country settings [3]. However, there are concerns
about the ability and willingness of individual private doctors to
implement the public health approach to ART management, and
about high costs in the for-profit private sector. To date there have
been no published comparisons of clinical and economic outcomes
of the provision of ART care to public patients between the private
sector and public sector.
In addition to the debates about public versus private ART
care, there are also questions about how frequently patients should
be followed up, and by whom. In the earlier years of ART
provision, patients were required to attend facilities for regular
consultations with doctors or nurses [4]. More recently, however,
there has been a move towards less frequent follow-up, and
towards task shifting from doctors to nurses, and from nurses to
counselors [5]. It is however unclear whether this changing
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intensity in follow-up will impact negatively on patient adherence
and outcomes.
We assessed the costs and outcomes of providing ART care for
public patients in the private versus public sector in two South
African ART programs where no co-payment from patients was
required: a grant-funded program providing care for public
patients in private practices and a public-sector program providing
care for public patients in public sector community clinics. We
utilized a newly developed Markov-model, which addresses many
of the limitations of existing models [6].
Methods
Study design
We assessed the costs and outcomes of ART provision in the
private-care and public-care models to provide care to public
sector dependent patients. We took the provider’s perspective and
only included ART-related costs: antiretroviral drugs, CD4+ cell
count (CD4) and viral load (VL) monitoring, toxicity laboratory
monitoring, and public clinic or private general practitioner (GP)
visits. We used Markov modeling to extrapolate primary data in
order to estimate results over 10 years and lifetime for costs, rates
of loss to follow-up and life years. Zero and three percent annual
discount rates were used. The model was developed using data
from the public-care cohort, and validated externally using data
from the private-care cohort. Uncertainty was assessed using
multi-way and probabilistic sensitivity analyses.
Study setting
ART care for patients in both programs followed the 2003
South African national guidelines, which were based on the 2003
World Health Organization guidelines for resource-limited settings
[7]. Patients were eligible for ART when they met the following
criteria: either a CD4 below 200 cells/mL or a WHO stage 4 illness
(other than extra-pulmonary tuberculosis) irrespective of the CD4
count. The first line ART regimen consisted of two nucleoside
reverse transcriptase inhibitors (NRTI), zidovudine (ZDV) or
stavudine (D4T) with lamivudine (3TC), with a non-nucleoside
reverse transcriptase inhibitor (NNRTI), nevirapine (NVP) or
efavirenz (EFV). Viral load and CD4 counts were monitored
6 monthly. Patients with confirmed virologic failure (two consec-
utive viral loads . = 5000 copies/ml) in spite of enhanced
adherence promotion, were switched to a second line regimen of
two NRTIs, ZDV and didanosine (DDI), in combination with a
boosted protease inhibitor, lopinavir/ritonavir (LPV/r). Safety
monitoring was limited to serum alanine aminotransferase (ALT),
complete blood count, and lipogram for patients on NVP, ZDV,
and LPV/r respectively.
Cohort Description
The public-care cohort was the Khayelitsha HIV treatment
program, which is a public sector program operating in an urban
area in Cape Town, South Africa. The program is jointly funded
by the state and a donor, Medecins Sans Frontieres. ART care was
provided at three primary care clinics. ART was initiated by
doctors but routine follow up was largely done by nurses. The
clinics operated on a queue system and therefore patients would
spend between 1–4 hours at the clinic. Counselors and peer-
educators played an important role in educating and encouraging
patients while they waited to see clinical staff. Most patients
returned to the clinic every month to collect medicines, attend
group or individual counseling sessions, and/or for clinical
assessments. We included data from the inception of the program
on 15 January 2000 until 25 Jan 2008.
The private-care cohort was the BroadReach Healthcare
program, a donor-funded (President’s Emergency Plan for AIDS
Relief (PEPFAR)) managed-care ART program. Patients were
recruited into the program at several urban and rural public sector
clinics in the Mpumulanga, Eastern Cape and Kwazulu-Natal
provinces in South Africa. ART care was provided by local
contracted general practitioners (GPs) in their private practices on
an appointment basis and visit frequency was pre-specified. The
private doctors had to successfully complete internet-based
training on the national ART guidelines before they could enroll
patients. Telephonic counseling support for the patients and
clinical guidance for the doctors was provided by Aid for AIDS, a
private sector disease management program. Patients collected
their medication from the doctors’ rooms monthly, but clinical
consultations were performed less frequently. We included data
from the inception of the program on 1 May 2005 until 31 July
2010. New patient enrollment was stopped in March 2008.
In both cohorts severely ill or complicated patients were referred
to secondary level public sector hospitals for further management
and then re-integrated back into the program once their condition
had stabilized. Data were entered prospectively into databases.
Deaths were ascertained by several mechanisms: (1) clinic staff or
private practice practitioners who learnt of a death from family
members or friends, would either complete a specific form and fax
it to a central office or capture it on a computer-based system
onsite; (2) staff and program administrators identified patients who
had missed several appointments and contacted a family member
or treatment supporter of the patient to determine whether the
patient was deceased and if so the date of death; and (3) the
patient’s South African identity number, where available, was used
to cross-reference the South African national death register to
establish whether a death was recorded.
We included adult patients (19 years and older) who started first
line ART within the programs and had a baseline CD4 count
below 200 cells/mL. The study intervals differed somewhat for
each cohort, although the median year of starting ART was 2005
in both cohorts. A patient’s follow-up period was truncated on the
date they either: transferred out of the program, died, on the study
end date, or on the last date seen if they were not seen within six
months of the end of the study period and their identity number
was not available (and we were therefore unable to ascertain
whether they had died).
Healthcare utilisation and cost data
GP or clinic utilisation was determined from the electronic
database records for both cohorts. The cost in South Africa Rands
(ZAR) for a public-sector clinic visit was determined from a
previously published estimate [4]. In that study, the unit clinic visit
costs included time allocations for nurses, doctors, and counselors,
and this has changed in more recent times due to increased task
shifting. Together with improved economies of scale and learning
by doing, cost would have fallen substantially had it not been for
substantial increases in doctor’s salaries over the same period. We
therefore decided to only use the consumer price index table [8] to
inflate costs to April 2010 levels. Private GP visit costs were
determined from contracted rates in April 2010.
Drug utilisation was divided into first line (2NRTIs and
NNRTI) and second line (2NRTIs and PI) therapy, and the
average utilisation of each drug was determined within each line of
therapy. Because estimates of ARV drug utilization were not
available within our dataset, we conservatively assumed that all
patients had received their ARVs each month and therefore
allocated full monthly ARV drug costs within the ART model.
A Model Comparing Private and Public ART Programs
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ARV drug costs were set at the public sector tender prices for April
2010.
There was some under-reporting of CD4 and VL monitoring,
and ARV laboratory toxicity monitoring was not recorded in both
programs. We conservatively assumed all patients underwent
laboratory monitoring as per the South African public-sector
guidelines. The guidelines recommended six monthly CD4 and
VL monitoring. Laboratory toxicity monitoring, which occurred
predominant in the first six months on ART, was limited to ZDV,
NVP, and LPV/r. We scaled the specific toxicity monitoring
utilisation associated with a specific ARV drug in accordance with
its relative proportion within the two regimen lines. All laboratory
costs were set at the public sector tender prices for April 2010. All
costs were converted from ZAR to United States Dollars (USD) in
April 2010 (7.34 ZAR per USD).
The Markov model framework, development and
uncertainty analysis
WHO stage, current CD4, and current VL were identified as
key determinants of lifetime costs and outcomes [9]. Many patients
categorized as ‘‘LTFU’’ in studies return to ART care and
therefore are not truly LTFU [10]. This is important as: (a) ART-
related resources are not consumed while a patient is LTFU, (b)
the CD4 count falls rapidly to pre-ART levels in patients who
interrupt ART [11], (c) additional resources are consumed in
patients restarting ART [9], (d) treatment interruptions increase
resistance to first line regimens [9][9][9][9][9](9)(9)(8), and (e)
treatment interruptions increase deaths [9] and attenuate CD4
recovery [12].
We based the structure of the Markov model on these
determinants of costs and outcomes as well as on our own analysis
of the public-care program – the larger of the two cohorts. We
implemented this Markov model in Treeage 2009 [13] and
populated it with parameter estimates derived in Stata 11 [14]
using survival models for time-to-event analyses and generalized
linear models for clinic/GP utilisation. We evaluated the model fit
and adjusted the model design where appropriate. Then, using the
data from the private-care program, we derived new parameter
estimates and evaluated the ability of the model to predict
outcomes and costs. This procedure allowed us to assess the
external validity of the model [4,15]. The model was run for two
durations: 10 years and until all members of each cohort were
dead (i.e. lifetime duration). Finally, we conducted probabilistic
sensitivity analysis to assess uncertainty. This entailed specifying
distributions on utilization and outcome parameters, where
possible and propagating uncertainty through the model by way
of first and second order Monte Carlo simulations. The models
were run using a 1 month cycle length [16,17].
The Markov Model
The overall Markov model was divided into two parts: an ART
model and a LTFU model (see figure 1). All patients started in the
ART model, and remained there until they either died or became
LTFU. Healthcare utilisation and mortality has been shown to be
significantly higher in the first 6 months on ART [4,6]. Therefore
the ART model was divided into two phases: 0–6 months on
starting or restarting ART and .6 months on ART. We defined
LTFU as defaulting ART for more than 6 months. Patients
entering the LTFU model remained there until they either died or
restarted ART. We used parametric survival analysis with an
exponential distribution to determine the transition probabilities to
outcomes (death, LTFU, CD4 category change, and VL category
change), and generalized regression models to determine utilisa-
tion (GP and clinic visits) within the Markov states. Covariates
included time on ART, on-ART CD4 category, on-ART VL
category, and year of starting ART (normalizing findings to 2005).
We assumed that non-HIV related deaths of a typical individual
(34 years) were included in the recorded deaths. We modeled the
increasing relative contribution of non-HIV related deaths over
time using the mortality curves for South Africa (less the typical
mortality for a 34 year old adult) before the onset of South Africa’s
HIV epidemic (prior to 1990).
In the first 6 months after starting or restarting ART, patients
were split according to their pre-ART CD4 count category (0–49
or 50–199 cells/mL), and remained within this CD4 category for
6 months. At the end of 6 months, the remaining patients (i.e. not
LTFU or dead) were distributed into the Markov states of the
.6 months on ART model using a competing risks regression
model with the pre-ART CD4 category as the only covariate. The
.6 months on ART phase was defined by fifteen Markov states.
These included: five on-ART CD4 categories (0–49, 5–199, 200–
349, 350–499, and $500 cells/mL) and three on-ART VL
categories (,1,000; 1,000–99,999; and $100,000 copies/mL).
Within each Markov cycle, we limited transitions between these
Markov states to either a CD4 or VL category change but not
both, as this reduced model complexity.
We distributed patients entering the LTFU model into the two
pre-ART CD4 categories (0–49 and 50–199 cells/mL) with the
relative proportions being derived from the observed data. Given
the limited LTFU data within our cohorts, we used the transition
probability from the higher to the lower pre-ART CD4 category
on a previously published natural history HIV model [4], and
adapted the transition probabilities from these CD4 categories to
death to match the observed trends in deaths within our cohorts.
We used a regression model to determine the transition probability
of restarting ART for patients LTFU, with time since first starting
ART as the covariate.
The transition probability from first line to second line ART
was determined separately within the two phases of the ART
model and the covariates for the regression model included pre-
ART CD4 category, on-ART VL category, on-ART CD4
category, and time since starting ART. Within the second line
ART model all transition probabilities were the same as the first
line ART model, but the ARV drug utilisation and therefore costs
differed. Patients within the LTFU model were assigned no ART-
related utilisation and therefore no costs.
Uncertainty analysis
We assessed the uncertainty in the data and model design using
probabilistic sensitivity analysis (first and second-order Monte
Carlo simulations). First-order simulations were used to capture
the variability in the simulated population and tracked the varying
paths taken by patients moving through the model in order.
Second-order simulations were used to capture the variability in
the parameter estimates by randomly sampling from the
triangular-shaped distribution for the parameter, which approx-
imated the 95% confidence interval. We ran 1,000 second-order
and 10,000 first-order simulations to determine the 95%
uncertainty intervals around the lifetime costs and outcomes. We
assessed uncertainty related to extrapolation of the data and the
generalizability of the model in three ways: (1) we externally
validated the model derived from public-care cohort using the
private-care cohort dataset, (2) we extrapolated our estimates over
10 year and life-time durations and compared the results, and (3)
we compared our outcomes and cost estimates with other
published studies. Finally, we assessed the uncertainty related to
analytical methods by comparing the findings with 0% and 3%
annual discounting of costs and outcomes.
A Model Comparing Private and Public ART Programs
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Scenario analysis
Clinic visit utilisation within the public-care program was
intensive due to a policy decision by the program managers that all
patients should be seen by a nurse or doctor every one to two
months. In more recent years, the clinic visit utilisation has been
substantially reduced to accommodate the growing number of
patients. We therefore explored the impact of reduced clinic visit
utilisation within the public-care program on the overall results.
Ethics statement
The study was approved by the Research Ethics Committee,
University of Cape Town. All patients signed consent for their
information to be entered into the central databases and analysed.
Anonymity was ensured using generated identifiers and all
personal data were deleted from the datasets.
Results
Cohorts
The characteristics and overall outcomes of the study cohorts
are described in Table 1. We included 6372 and 963 patients from
the public-care and private-care programs respectively. Median
follow-up time on ART was shorter in the public-care cohort. No
patients were transferred out to other facilities from the private-
care program. The model fit diagnostics for both the private-care
and public-care programs are shown in figures S1 and S2
respectively. These include current CD4, current VL, line of
therapy and status (current, LTFU or dead).
Health care utilization and unit costs in Markov states
Over the study period, 212,175 clinic visits in the public-care
cohort and 10,477 GP visits in the private-care cohort were
recorded. The contracted rate for a GP visit was 31.04 USD and
the estimated cost of 24.53 USD for a clinic visit was derived by
inflating the cost estimate from a previous publication [4]. The
average monthly GP/clinic utilisation (with 95% confidence
intervals) and the cost estimates are shown in table S1. Within
both cohorts, utilisation was highest in patients restarting ART
and, to a lesser extent, during the 0–6 months after starting ART,
compared with the .6 months on ART phase. In this latter phase,
monthly visit utilisation was lower in both cohorts. Importantly,
the public-care cohort had approximately 2 to 4 times higher visit
utilisation within the .6 months on ART phase compared with
the private-care cohort.
The South African public sector guidelines were used for
laboratory utilisation – the costs and utilisation are shown in
table S2. CD4 and VL were taken 6 monthly, whilst other
laboratory utilisation related to toxicity monitoring depended on
the specific antiretroviral drugs and was higher in the first
6 months on ART.
Figure 1. Markov model diagram.
doi:10.1371/journal.pone.0053570.g001
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The utilisation of individual drugs within the first and second
line ART regimens, the ART-related costs, and the hazard
coefficients and transition probabilities for the model describing
the transition between first and second line ART are shown in
table S3 and figure S3. We assumed 100% utilisation of both ARV
drugs and laboratory tests while within the ART model. The
public-care cohort had higher zidovudine but lower efavirenz
utilisation in the first line ART regimen. The public-care cohort
had higher didanosine utilisation in the second line ART regimen.
The transition probability of moving to second line ART was
lowest in the 0–6 months after starting ART and highest in the 0–
6 months after restarting ART. In the .6 month on ART phase,
the transition probability of moving to second line ART decreased
with lower VL and higher CD4 categories respectively, increased
with time on ART and plateaued at about 3 years. The transition
probabilities to second line ART were generally lower in the
private-care cohort. The estimated distribution of time between
first and second line ART was 61% and 39% in the public-care
cohort versus 66% and 34% in the private-care cohort.
Effectiveness
The transition probabilities for the CD4 and VL models on
ART are shown in table S4. The baseline CD4 category
distribution for patients starting ART was similar in both cohorts:
30% in the 0–49 cells/mL category and 70% in the 50–199 cells/
mL category. A lower baseline CD4 category was associated with a
lower CD4 category distribution after 6 months on ART, but
lower baseline CD4 category did not impact on the VL
distribution. Public-care patients were more likely than private-
care patients to have VL ,1000 copies/ml (92% versus 87%) and
CD4 counts $200 cells/mL (64% versus 42%) after the first
6 months on ART. This trend was similar for patients restarting
ART, but the outcomes were worse: 61% and 43% had VL,1000
copies/ml, and 49% and 63% had CD4 counts ,200 cells/mL for
patients in the public-care and private-care cohorts respectively.
The transition probabilities and hazard coefficients for deaths
on ART are shown in table 2. The transition probability to death
was highest in the first 3 months on ART and in patients with a
low pre-ART CD4 category. The transition probability to death
was lowest for the first 6 months after restarting ART. For patients
in the .6 months on ART phase, the transition probability to
death decreased with lower VL category, higher CD4 category,
and time on ART (using a Gompertz time function). The median
of the Gompertz time function was 20 months in both cohorts, but
the scaling constant was higher in the private-care cohort (1.19
versus 1.04). Thus there were more early deaths in the private-care
cohort.
The hazard coefficients and transition probabilities related to
the LTFU model are shown in table 3. The transition probability
from ART to LTFU was lowest in the first 6 months after starting
ART and highest in the first 6 months after restarting ART.
Thereafter, the transition probability from ART to LTFU
increased with higher VL category, lower CD4 category, and
time on ART. We modeled the effect of time on ART by adapting
the Gompertz function so that it plateaued. The median of the
adapted Gompertz function was longer (12 months versus 8) and
the scaling constant has higher (1.5 versus 0.5) in the public-care
compared with the private-care cohort. We distributed patients
entering the LTFU model as follows based on our analysis of the
data: 30% to the 0–49 cells/mL and 70% to the 50–199 cells/mL
CD4 categories. The transition probability from LTFU to
restarting ART was higher in the private-care cohort (26% versus
13%) and independent of LTFU CD4 category.
The highest death rates were observed within the first year on
ART for both cohorts, especially in the private-care cohort: 8%
and 15% had died by 12 months and 32% and 39% had died by
120 months in the public-care and private-care cohorts respec-
tively. The distribution of VL categories stabilized by 3 years to
90% and 85% of patients having a VL ,1000 copies/ml within
public and private-care cohorts respectively. The distribution of
CD4 categories was more dynamic over time and the private -care
cohort fared better with 50% versus 40% of patients having a CD4
$500 cells/mL by 10 years. The percentage of patients who were
alive and still on ART stabilized at approximately 80% for both
cohorts, although the private-care cohort achieved this earlier due
to generally higher transition probabilities to and from LTFU.
Ten-year and lifetime costs, outcomes, probabilistic
sensitivity and scenario analysis
We ran Monte Carlo simulations for 10 years and until
everyone had died to generate lifetime costs and outcomes
together with their 95% confidence intervals, as shown in table 4.
The conclusions we derived from the 10 year and lifetime
estimates (with and without discounting) were congruent: the
private-care program was approximately as effective, but was less
costly than the public-care program. These reduced costs were
predominantly driven by the lower level of utilisation in the
private-care program. Given that the outcomes between the two
programs were not significantly different, this finding suggests that
reduced visit utilization has the potential to be cost saving
(reducing costs without impacting on patient outcomes).
When we reduced the frequency of clinic visits in the
.6 months on ART phase by two-thirds in the public-care
program (in line with the changes introduced in late 2011 by the





IQR (28,7 to 39,3) (30,4 to 41,9)
Sex (%)
Female 67,7 68,3
CD4 count (cells/ml) baseline
Median 99 92
IQR (44 to 161) (44 to 146)
Unknown 435 3
Viral load (log10) baseline
Median 5,1 5,1




IQR (11,7 to 33,4) (29 to 57,8)
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program administrators), the estimated 10-year and lifetime costs
within the public-care program approximated the levels observed
in the private-care program. In other words, the programs were
equivalent in terms of costs and outcomes.
Discussion
We determined that the private-care program had lower costs
and similar outcomes to the public-care program at the time of the
study using a novel Markov model. Key differences between the
programs were less frequent visits and higher rates of returning to
care after loss to follow-up in the private-care program, and lower
early death rates on ART, but more deaths while LTFU in the
public-care program. We estimated that the recent shifts towards
less frequent visits in the public-care ART program would achieve
large cost savings, making the costs of the two programs similar.
These findings suggest that properly managed private-care
programs can ease the burden of ART care in endemic countries
by looking after public sector patients without increasing costs.
Further, reducing clinic visits may be a viable strategy to save costs
while maintaining outcomes in public sector programs.
Our Markov model included several significant improvements
on previously published models [4,18–22]. First, we separated out
the first six months on ART, as outcomes and costs in this period
are driven by baseline CD4 count and program protocols (higher
frequency of clinic visits and toxicity monitoring) [6]. Second, we
developed a novel LTFU model, in which patients transitioned
between ART and LTFU, changed baseline CD4 count within
LTFU, and transitioned to death within LTFU. Third, we
developed Markov models to account for CD4 and VL category
changes within the ART and LTFU models. Fourth, we developed
a more detailed model describing the transition between first line
and second line ART, which is a major cost driver [23]. Fifth, the
model included the impact of time on ART on the transition to
LTFU, death, and second line ART. Finally, we assessed the
external validity of the model by first developing the model using
the public-care program data and then validating it using private-
care program data. The fact that our novel Markov model was
able to describe the data from two very different models of ART
care suggests that its utility may be generalizable.
We are aware of one other study that compared costs and
outcomes after 1 year in public-care and private-care programs for
Table 2. Transition probabilities and hazard coefficients for deaths on antiretroviral therapy.
Variables
Transition probabilities and hazard coefficients (95% CI) per 1
month cycle
Public-care Private-care
First 6 months after starting antiretroviral therapy
Transition probability
3 months CD4 0–49 cells/mL 0,035 (0,029 to 0,044) 0,040 (0,029 to 0,056)
3 months CD4 50–199 cells/mL 0,010 (0,008 to 0,012) 0,017 (0,013 to 0,022)
6 months CD4 0–49 cells/mL 0,011 (0,010 to 0,014) 0,027 (0,021 to 0,036)
6 months CD4 50–199 cells/mL 0,003 (0,003 to 0,004) 0,011 (0,009 to 0,014)
First 6 months after restarting antiretroviral therapy
Transition probability: 0–6 months 0,008 (0,004 to 0,016) 0,004 (0,001 to 0,010)
.6 months on antiretroviral therapy
Hazard coefficient due to CD4 and VL
CD4 0–49 cells/mL VL ,1,000 copies/ml 25,01 25,03
CD4 0–49 cells/mL VL 1,000–100,000 copies/ml 24,71 24,69
CD4 0–49 cells/mL VL .100,000 copies/ml 23,83 24,13
CD4 50–199 cells/mL VL ,1,000 copies/ml 26,00 26,5
CD4 50–199 cells/mL VL 1,000–100,000 copies/ml 25,69 26,16
CD4 50–199 cells/mL VL ,1000 copies/ml 24,82 25,6
CD4 200–349 cells/mL VL .100,000 copies/ml 27,25 27,48
CD4 200–349 cells/mL VL 1,000–100,000 copies/ml 26,94 27,14
CD4 200–349 cells/mL VL ,1000 copies/ml 26,07 26,58
CD4 350–499 cells/mL VL .100,000 copies/ml 27,63 28,53
CD4 350–499 cells/mL VL 1,000–100,000 copies/ml 27,32 28,19
CD4 350–499 cells/mL VL .100,000 copies/ml 26,45 27,63
CD4 $500 cells/mL VL ,1,000 copies/ml 27,76 28,16
CD4 $500 cells/mL VL 1,000–100,000 copies/ml 27,46 27,82
CD4 $500 cells/mL VL .100,000 copies/ml 26,58 27,26
Hazard coefficients for Gompertz function
alpha 0,93 (0,52 to 1,34) 1,73 (1,17 to 2,28)
beta – half-life (months) 20 20
doi:10.1371/journal.pone.0053570.t002
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Table 3. Transition probabilities and hazard coefficients related to loss to follow-up.
Variables Transition probabilities and hazard coefficients (95%) per 1 month cycle
Public-care Private-care
Transitions within ART model
Transition probability to LTFU within 0–6 months on ART
On starting ART 0,0085 (0,0080 to 0,0091) 0,0006 (0,0006 to 0,0006)
On restarting ART 0,0270 (0,0205 to 0,0356) 0,0251 (0,0251 to 0,0251)
Hazard coefficient to LTFU within .6 months on ART
CD4 0–49 cells/mL VL ,1,000 copies/ml 24,7 25,13
CD4 0–49 cells/mL VL 1,000–100,000 copies/ml 23,79 24,16
CD4 0–49 cells/mL VL .100,000 copies/ml 24,00 24,37
CD4 50–199 cells/mL VL ,1,000 copies/ml 25,31 25,44
CD4 50–199 cells/mL VL 1,000–100,000 copies/ml 24,4 24,47
CD4 50–199 cells/mL VL ,1000 copies/ml 24,61 24,68
CD4 200–349 cells/mL VL .100,000 copies/ml 25,73 24,52
CD4 200–349 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 200–349 cells/mL VL ,1000 copies/ml 25,03 23,76
CD4 350–499 cells/mL VL .100,000 copies/ml 25,73 24,52
CD4 350–499 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 350–499 cells/mL VL .100,000 copies/ml 25,03 23,76
CD4 $500 cells/mL VL ,1,000 copies/ml 25,73 24,52
CD4 $500 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 $500 cells/mL VL .100,000 copies/ml 25,03 23,76
Hazard coefficients for Gompertz function
alpha 1,5 0,5
beta – half-life (months) 12 8
Initial distribution within LTFU model
CD4 0–49 cells/mL 0,278 (0,255 to 0,302) 0,243 (0,217 to 0,269)
CD4 50–199 cells/mL 0,722 (0,745 to 0,698) 0,757 (0,783 to 0,731)
Transitions within LTFU model
Transition probability between CD4 category
CD4 50–199 to CD4 0–49 cells/mL 0,005 (0,005 to 0,005) 0,006 (0,006 to 0,006)
Transition probability back to ART
CD4 0–199 cells/mL 0,134 (0,128 to 0,141) 0,146 (0,139 to 0,154)
Transition probability to death
CD4 0–49 cells/mL 0,006 (0,005 to 0,008) 0,006 (0,005 to 0,008)
CD4 50–199 cells/mL 0,001 (0,001 to 0,017) 0,001 (0,001 to 0,017)
doi:10.1371/journal.pone.0053570.t003
Table 4. 10 year and lifetime estimates of cost and outcomes of the private-care and public-care programs.
Treatment option 10 year estimates Lifetime estimates
Costs (95% CI) in USD Life years gained (95% CI) Costs (95% CI) in USD Life years gained (95% CI)
Undiscounted
Public-care 8,825 (8,614 to 9,036) 7.6 (7.4 to 7.8) 18,734 (17,385 to 20,083) 14.1 (13.2 to 15.0)
Private-care 6,187 (5,997 to 6,377) 7.2 (7.0 to 7.4) 13,062 (12,077 to 14,047) 14.0 (13.1 to 14.8)
Discounted
Public-care 7,688 (7,513 to 7,863) 6.7 (6.5 to 6.8) 13,305 (12,588 to 14,022) 10.4 (9.9 to 10.9)
Private-care 5,407 (5,250 to 5,564) 6.3 (6.2 to 6.5) 9,273 (8,704 to 9,842) 10.0 (9.4 to 10.5)
doi:10.1371/journal.pone.0053570.t004
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public sector patients [24]. Their private-care program had
significantly lower costs due to fewer GP visits and poorer patient
retention than their public care program. The costs of providing
ART care were similar, although patient retention was better in
our programs. Lifetime analyses using Markov models populated
with data from resource-limited settings predicted varying survival
on ART (6 to 13 years) and varying discounted total costs (3,000
to 9,500 USD from the provider’s perspective) [16,18,21–
23,25,26]. Many of these models were developed using short
term follow up data. Furthermore, retention within ART
programs and cost of providing ART care in resource-limited
settings varies dramatically [27,28]. We estimated that average
survival on ART was longer than most resource-limited setting
model estimates.
The patients included in this analysis were public-sector patients
receiving ART care in accordance with WHO public sector ART
program guidelines. Therefore the results from this analysis have
important policy implications that are relevant to other resource-
limited settings. The rapid expansion of access to ART in
resource-limited settings is both needed [29] and challenging [30].
Our findings suggest that managed private-care for public sector
patients could be used to increase access to ART, provided that
the private practices follow national protocols and that loss to
follow-up is managed – key components of the private-care
program in our study. A similar model was implemented in
Botswana to expand access to ART in areas where limited public-
sector resources were available, by utilising doctors working in
private practice to look after public sector patients [2]. Their
findings suggested that ART care coverage was extended by 10%
and public-sector programs were strengthened by the interaction
[2]. We found that reduced utilisation of clinic visits, especially
after the initial six months of care, would considerable lower costs
of public-care programs. Finally, our model predicted that LTFU
contributed significantly to deaths, utilisation of ART-related
resources (on restarting ART), and attenuated CD4 recovery. This
suggests that focusing on reducing LTFU could be a cost-saving
strategy.
There were several limitations to our study. First, the findings in
our study are based on a model that extrapolated the trends we
observed over the first 3–5 years on ART predominantly. Second,
we limited costs in this study to direct ART care costs, while the
other components of care represent a significant portion of total
costs [31]. Data on these other cost components were not
available. Third, we did not account for the impact of adherence
on the total cost of ART drugs, nor the changing composition of
specific drugs within the therapy lines over time [31,32]. Fourth,
given the limited data on actual laboratory utilisation, especially
for toxicity monitoring, we set the laboratory utilisation to those
recommended in national guidelines. Fifth, it is likely that the
patients within the public-care program had better access to HIV
clinic services than typical public-sector patients in South Africa,
and this would have increased costs, and possibly enhanced patient
retention and improved outcomes [33]. Sixth, the relative
proportions of individual drugs within the lines of therapy differed
between cohorts: the average ART costs were marginally lower in the
private-care program and the different regimens may have impacted the
outcomes. Seventh, given the different models of ART care and
different settings in which the programs were based, these
programs were not completely comparable and therefore the
overall conclusions in terms of costs and outcomes cannot be
regarded as definitive. Finally, our public sector clinic visit cost was
based on secondary data, which may not capture recent
programmatic changes in ART provision (including task shifting)
and economies of scale and scope. However, it is difficult to predict
the extent to which this unit cost may under or overestimate costs.
In moving towards universal access to ART, South Africa intends
to offer ARVs from all primary care facilities, which will have
implications for the efficiency of service provision and the resulting
unit cost. Economies or diseconomies of scale can equally arise in
small new facilities during start-up and in older large facilities with
high patient volumes.
While analyses of provider costs and patient outcomes are
crucial in guiding resource allocation for HIV care, it is equally
important to consider barriers to patient access, particularly within
the context of lifelong care [34]. Evidence suggests that the key
barriers to ongoing ART care include the cost of transport to
facilities as well as the opportunity cost associated with long
waiting times in facilities [34,35]. Less frequent visits would
mitigate these access barriers. One advantage of private care is
that waiting times are usually shorter.
Conclusions
In conclusion, we have developed a novel Markov model that
has the potential to improve the accuracy of estimations of future
costs and outcomes of long-term ART care. We have used this
model to evaluate two ART programs, and have shown that
managed private-care ART programs have the potential to
complement the public sector platform in resource poor settings,
thereby enhancing and sustaining coverage of patients in need.
Our findings suggest that cost savings could be achieved through
reducing clinic utilization without compromising patient out-
comes.
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